FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968487988> ?p ?o ?g. }

• W1968487988 endingPage "2458" @default.
• W1968487988 startingPage "2448" @default.
• W1968487988 abstract "Of 133 patients with advanced urothelial tract cancer given methotrexate (MTX), vinblastine (VBL), Adriamycin (ADR) (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (DDP) (M-VAC regimen), significant tumor regression occurred in 72% ± 8% of 121 with transitional cell carcinoma (TCC) evaluable for response. Complete remission (CR) was achieved in 36% ± 9% of patients, of whom 11% required the addition of surgical resection of residual disease. Although 68% of CR patients have relapsed, CR median survival will exceed 38 months compared with 11 months for partial (36%) and minor (6%) responders, and 8 months for nonresponders: 2-year and 3-year survivals were 68% and 55%, respectively, versus 0% to 7% for the remaining patients. Sixteen percent of responders developed brain lesions, half of whom had no systemic relapse at the time of progression. Three patients with non-TCC histologies did not respond. In 32 patients who had pathologic restaging, the clinical (T) understaging (T < pathologic [P] restaging) error was 35%. Although all metastatic sites showed evidence of tumor regression, CR was noted more frequently in lung, in intraabdominal lymph nodes and masses, and in bone (24% to 35%); the rate for hepatic lesions was 15%. There were 52% of 21 N3–4Mo patients who achieved CR versus 33% of 100 with No-+M+ lesions. Toxicity was significant with 4 (3%) drug-related deaths, 25% incidence of nadir sepsis, 58% ⩾ 3+ myelosuppression, and 49% with mucositis. Responsiveness of metastasis in various sites, patterns of relapse, and the usefulness of the new CR response criteria are reported, as is the current status of cisplatin and methotrexate combination regimens. Cancer 64:2448–2458, 1989." @default.
• W1968487988 created "2016-06-24" @default.
• W1968487988 creator A5004913924 @default.
• W1968487988 creator A5004985848 @default.
• W1968487988 creator A5037792721 @default.
• W1968487988 creator A5048541532 @default.
• W1968487988 creator A5054035174 @default.
• W1968487988 creator A5055533470 @default.
• W1968487988 creator A5056302631 @default.
• W1968487988 creator A5061514235 @default.
• W1968487988 creator A5066784176 @default.
• W1968487988 creator A5067094107 @default.
• W1968487988 creator A5070626557 @default.
• W1968487988 creator A5072443682 @default.
• W1968487988 creator A5072850546 @default.
• W1968487988 creator A5072952391 @default.
• W1968487988 creator A5073076957 @default.
• W1968487988 creator A5076312024 @default.
• W1968487988 creator A5089199323 @default.
• W1968487988 date "1989-12-15" @default.
• W1968487988 modified "2023-10-11" @default.
• W1968487988 title "Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse" @default.
• W1968487988 cites W1887965852 @default.
• W1968487988 cites W2071772756 @default.
• W1968487988 cites W2338649218 @default.
• W1968487988 cites W23441172 @default.
• W1968487988 cites W2423431034 @default.
• W1968487988 cites W2474434662 @default.
• W1968487988 cites W4293241248 @default.
• W1968487988 cites W55867272 @default.
• W1968487988 doi "https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7" @default.
• W1968487988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2819654" @default.
• W1968487988 hasPublicationYear "1989" @default.
• W1968487988 type Work @default.
• W1968487988 sameAs 1968487988 @default.
• W1968487988 citedByCount "633" @default.
• W1968487988 countsByYear W19684879882012 @default.
• W1968487988 countsByYear W19684879882013 @default.
• W1968487988 countsByYear W19684879882014 @default.
• W1968487988 countsByYear W19684879882015 @default.
• W1968487988 countsByYear W19684879882016 @default.
• W1968487988 countsByYear W19684879882017 @default.
• W1968487988 countsByYear W19684879882018 @default.
• W1968487988 countsByYear W19684879882019 @default.
• W1968487988 countsByYear W19684879882020 @default.
• W1968487988 countsByYear W19684879882021 @default.
• W1968487988 countsByYear W19684879882022 @default.
• W1968487988 countsByYear W19684879882023 @default.
• W1968487988 crossrefType "journal-article" @default.
• W1968487988 hasAuthorship W1968487988A5004913924 @default.
• W1968487988 hasAuthorship W1968487988A5004985848 @default.
• W1968487988 hasAuthorship W1968487988A5037792721 @default.
• W1968487988 hasAuthorship W1968487988A5048541532 @default.
• W1968487988 hasAuthorship W1968487988A5054035174 @default.
• W1968487988 hasAuthorship W1968487988A5055533470 @default.
• W1968487988 hasAuthorship W1968487988A5056302631 @default.
• W1968487988 hasAuthorship W1968487988A5061514235 @default.
• W1968487988 hasAuthorship W1968487988A5066784176 @default.
• W1968487988 hasAuthorship W1968487988A5067094107 @default.
• W1968487988 hasAuthorship W1968487988A5070626557 @default.
• W1968487988 hasAuthorship W1968487988A5072443682 @default.
• W1968487988 hasAuthorship W1968487988A5072850546 @default.
• W1968487988 hasAuthorship W1968487988A5072952391 @default.
• W1968487988 hasAuthorship W1968487988A5073076957 @default.
• W1968487988 hasAuthorship W1968487988A5076312024 @default.
• W1968487988 hasAuthorship W1968487988A5089199323 @default.
• W1968487988 hasConcept C121608353 @default.
• W1968487988 hasConcept C126322002 @default.
• W1968487988 hasConcept C126894567 @default.
• W1968487988 hasConcept C141071460 @default.
• W1968487988 hasConcept C2776694085 @default.
• W1968487988 hasConcept C2777132456 @default.
• W1968487988 hasConcept C2778065480 @default.
• W1968487988 hasConcept C2778384902 @default.
• W1968487988 hasConcept C2778496288 @default.
• W1968487988 hasConcept C2780352672 @default.
• W1968487988 hasConcept C2781059491 @default.
• W1968487988 hasConcept C2781413609 @default.
• W1968487988 hasConcept C71924100 @default.
• W1968487988 hasConcept C90924648 @default.
• W1968487988 hasConceptScore W1968487988C121608353 @default.
• W1968487988 hasConceptScore W1968487988C126322002 @default.
• W1968487988 hasConceptScore W1968487988C126894567 @default.
• W1968487988 hasConceptScore W1968487988C141071460 @default.
• W1968487988 hasConceptScore W1968487988C2776694085 @default.
• W1968487988 hasConceptScore W1968487988C2777132456 @default.
• W1968487988 hasConceptScore W1968487988C2778065480 @default.
• W1968487988 hasConceptScore W1968487988C2778384902 @default.
• W1968487988 hasConceptScore W1968487988C2778496288 @default.
• W1968487988 hasConceptScore W1968487988C2780352672 @default.
• W1968487988 hasConceptScore W1968487988C2781059491 @default.
• W1968487988 hasConceptScore W1968487988C2781413609 @default.
• W1968487988 hasConceptScore W1968487988C71924100 @default.
• W1968487988 hasConceptScore W1968487988C90924648 @default.
• W1968487988 hasIssue "12" @default.
• W1968487988 hasLocation W19684879881 @default.
• W1968487988 hasLocation W19684879882 @default.
• W1968487988 hasOpenAccess W1968487988 @default.

• next